Literature DB >> 25924241

Authors' reply.

S K Sahu, S Giri, N Gupta.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 25924241      PMCID: PMC4943420     

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


× No keyword cloud information.
Sir, We are happy that our manuscript is being read with great interest. I would like to address the queries raised on our manuscript.[1] The role of steroids in transverse myelitis due to infection is controversial. Some studies have found IV methylprednisolone[2] to be useful while some studies have not. In view of the above reports, we planned to give IV methylprednisolone pulse along with antituberculous therapy. There are reports of worsening of the existing symptoms or the appearance of new lesions in patients who initially respond well to the antituberculous therapy.[34] However, none of our cases had such a paradoxical worsening clinically. We also did not witness patients with transverse myelitis to have discitis, vertebral body involvement, or abscess.
  4 in total

Review 1.  Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients.

Authors:  V C C Cheng; P L Ho; R A Lee; K S Chan; K K Chan; P C Y Woo; S K P Lau; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-11-07       Impact factor: 3.267

2.  Conservative treatment of tuberculosis of the lumbar and lumbosacral spine.

Authors:  Myung-Sang Moon; Young-Wan Moon; Jeong-Lim Moon; Sung-Sim Kim; Doo-Hoon Sun
Journal:  Clin Orthop Relat Res       Date:  2002-05       Impact factor: 4.176

3.  Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide.

Authors:  B M Greenberg; K P Thomas; C Krishnan; A I Kaplin; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

4.  Longitudinal extensive transverse myelitis due to tuberculosis: a report of four cases.

Authors:  S Ekinci; F Akyildiz; S Sari; S Akpancar
Journal:  J Postgrad Med       Date:  2015 Apr-Jun       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.